Supplementary Figure 1 Supplementary Figure 1 Schematic depiction of the tandem Fc GDF15.
Supplementary Figure 2 Supplementary Figure 2 Gfral mrna levels in the brains of both wild-type and knockout Gfral mice (n = 2/group) measured by quantitative RT-PCR.
Supplementary Figure 3 a b c d Supplementary Figure 3 GDF15 does not suppress body weight and food intake in female Gfral knockout mice. (a-d) Starting body weight (a), percentage body weight change (b), cumulative food intake (c) and OGTT on day 13 (d) of normal chow-fed, 10 week old female wild-type (n = 4/group) (left graphs) or Gfral / (KO) mice (n = 4/group) (right graphs) treated with Fc-GDF15 (0.1 mg/kg, intraperitoneal injection, every other day) or vehicle. Values are means and s.e.m. Body weight changes from baseline were analyzed in repeated measurement model with TOEPLITZ covariance matrix. Group effect was tested at each day. Bonferroni corrections were applied to post hoc multiple comparisons as shown in figures to control within day Type I error. Between day multiplicity adjustments were not applied. Cumulative food intakes were analyzed in separated one-way analysis of variance (ANOVA) models at each day. Bonferroni corrections were applied to post hoc multiple comparisons as shown in figures without further between day multiplicity adjustments. Log transformations were applied to Glucose measurements followed by the same repeated measurement model and post hoc multiple comparisons as described before. *P<0.05; **P <0.01; ***P< 0.001.
Supplementary Figure 4 a b c d Supplementary Figure 4 Daily treatment of recombinant native GDF15 does not suppress body weight and food intake in Gfral knockout mice. (a-c) Starting body weight (a), percentage body weight change (b) and cumulative food intake (c) of normal chow-fed, 10 week old female wild-type (n = 6/group) or Gfral / (KO) mice (n = 5 for vehicle group and n = 6 for treatment group) treated with recombinant native GDF15 (0.1 mg/kg, intraperitoneal injection, daily) or vehicle. (d) Plasma exposure of recombinant native GDF15 in both wild-type or Gfral / (KO) mice after single dose of 0.1 mg/kg injection. Values are means and s.e.m. Body weight changes from baseline were analyzed in repeated measurement model with TOEPLITZ covariance matrix. Group effect was tested at each day. Bonferroni corrections were applied to post hoc multiple comparisons as shown in figures to control within day Type I error. Between day multiplicity adjustments were not applied. Cumulative food intakes were analyzed in separated one-way analysis of variance (ANOVA) models at each day. Bonferroni corrections were applied to post hoc multiple comparisons as shown in figures without further between day multiplicity adjustments. *P<0.05; **P <0.01; ***P< 0.001.
Supplementary Figure 5 Supplementary Figure 5 GDF15 does not activate RET phosphorylation in SH-SY5Y cells overexpressing GFRAL and RET. Left panel: Western blot analysis of pret and total-ret from parental RET stable SH-SY5Y cells treated with native GDNF and GFRA1. Right panel: Western blot analysis of pret and total-ret from RET stable SH-SY5Y cells transient transfected with C-terminal FLAG tagged human GFRAL stimulated with either native GDF15 or Fc-GDF15. Western blot is a representative one from two independent experiments with a single biological replicate run per gel. Uncropped Western blot images are shown in Supplementary Fig. 6.
Supplementary Figure 6 a b c Supplementary Figure 6 Full-scans of Western blots. (a-c) Full-sized images of Western blots from Figure 1a (a), Figure 1g (b) and Supplementary Figure 5 (c). Red boxes highlight areas that were cropped and are displayed in the indicated figures. Western blot membranes of Figure 6g were cut out between 100 kda and 250 kda to detect p-ret and total RET.
Supplementary Table 1